Ionis Pharmaceuticals (IONS) Stock: Falls 2.23% Despite Roche’s Breakthrough Phase 3 Kidney Trial Results
TLDR IONS stock slides 2.23% to $42.93 despite Roche’s Phase 3 kidney trial success. Roche’s sefaxersen cuts proteinuria 43.1% in…
Market coverage 1 stories
TLDR IONS stock slides 2.23% to $42.93 despite Roche’s Phase 3 kidney trial success. Roche’s sefaxersen cuts proteinuria 43.1% in…